Mabeta, Peaceful LucyHull, RodneyDlamini, Zodwa2023-07-192023-07-192022-01-15Mabeta, P.; Hull, R.; Dlamini, Z. LncRNAs and the Angiogenic Switch in Cancer: Clinical Significance and Therapeutic Opportunities. Genes 2022, 13, 152. https://DOI.org/10.3390/genes13010152.2073-4425 (online)10.3390/genes13010152http://hdl.handle.net/2263/91544Angiogenesis is one of the hallmarks of cancer, and the establishment of new blood vessels is vital to allow for a tumour to grow beyond 1–2 mm in size. The angiogenic switch is the term given to the point where the number or activity of the pro-angiogenic factors exceeds that of the anti-angiogenic factors, resulting in the angiogenic process proceeding, giving rise to new blood vessels accompanied by increased tumour growth, metastasis, and potential drug resistance. Long noncoding ribonucleic acids (lncRNAs) have been found to play a role in the angiogenic switch by regulating gene expression, transcription, translation, and post translation modification. In this regard they play both anti-angiogenic and pro-angiogenic roles. The expression levels of the pro-ongiogenic lncRNAs have been found to correlate with patient survival. These lncRNAs are also potential drug targets for the development of therapies that will inhibit or modify tumour angiogenesis. Here we review the roles of lncRNAs in regulating the angiogenic switch. We cover specific examples of both pro and anti-angiogenic lncRNAs and discuss their potential use as both prognostic biomarkers and targets for the development of future therapies.en© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.Vascular endothelial growth factor (VEGF)Metastasis-associated lung adeno-carcinoma transcript 1HOX antisense intergenic RNAMaternally expressed gene3MANTISMyocardial infarction associated transcriptLong noncoding ribonucleic acids (lncRNAs)SDG-03: Good health and well-beingArticle